← Leaderboards
Christina Paige Cargill
Qrono, Inc
$915,377
Attributed
$915,377
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $613K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$915,377 · 2
By mechanism
R41$915,377 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Enteral”
- Michelle Rives · Baylor College Of Medicine$14,460,421
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Eric Anderson · Columbia University Health Sciences$11,474,975
- Jinsy Andrews · Columbia University Health Sciences$11,474,975
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Sabrina Paganoni · Massachusetts General Hospital$9,298,517
Research focus
EnteralHistologyCustomEfficacy EvaluationHeart HypertrophyHigh Pressure Liquid ChromatographyClinical DevelopmentCoupledCollaborationsDoseFutureGastrointestinal Tract StructureAnti-Inflammatory AgentsAgonist-Amp-Activated Protein Kinase5&AposAnimalsCellsAdverse EffectsClinical TrialsDendritic CellsDesignFlow CytometryImmune
Grant awards (3)
Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$302,409
R41 · FY2025 · DK · contact PI
Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes$306,500
R41 · FY2024 · AI · contact PI
Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$306,468
R41 · FY2024 · DK · contact PI